Aeglea Biotherapeutics Inc.’s Lock-Up Period Set To End on October 4th (NASDAQ:AGLE)
Aeglea Biotherapeutics’ (NASDAQ:AGLE) lock-up period will end on Tuesday, October 4th. Aeglea Biotherapeutics had issued 5,000,000 shares in its IPO on April 7th. The total size of the offering was $50,000,000 based on an initial share price of $10.00. After the expiration of Aeglea Biotherapeutics’ lock-up period, major shareholders and company insiders will be able to sell their shares of the company.
Separately, Zacks Investment Research cut Aeglea Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 11th.
Shares of Aeglea Biotherapeutics (NASDAQ:AGLE) traded down 3.61% during mid-day trading on Friday, reaching $6.41. The company’s stock had a trading volume of 12,245 shares. Aeglea Biotherapeutics has a 12-month low of $3.89 and a 12-month high of $12.75. The firm’s market cap is $85.96 million. The firm’s 50-day moving average price is $6.38 and its 200 day moving average price is $6.58.
Aeglea Biotherapeutics (NASDAQ:AGLE) last announced its earnings results on Tuesday, August 9th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by $0.03. On average, analysts expect that Aeglea Biotherapeutics will post ($4.77) EPS for the current year.
A number of hedge funds have recently made changes to their positions in AGLE. Ghost Tree Capital LLC bought a new stake in shares of Aeglea Biotherapeutics during the second quarter valued at about $243,000. Perceptive Advisors LLC acquired a new stake in Aeglea Biotherapeutics during the second quarter worth $515,000. Finally, VHCP Management II LLC acquired a new stake in Aeglea Biotherapeutics during the second quarter worth $1,527,000. 40.71% of the stock is currently owned by institutional investors and hedge funds.
About Aeglea Biotherapeutics
Aeglea BioTherapeutics, Inc is a biotechnology company. The Company is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. Its engineered human enzymes are designed to degrade specific amino acids in the blood.
Receive News & Stock Ratings for Aeglea Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Biotherapeutics Inc. and related stocks with our FREE daily email newsletter.